RECOMBINANT TAT PROTEIN INHIBITS MACROPHAGE CYTOTOXICITY (MEETING ABSTRACT) NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


RECOMBINANT TAT PROTEIN INHIBITS MACROPHAGE CYTOTOXICITY (MEETING ABSTRACT)

Proc Annu Meet Am Assoc Cancer Res; 33:A1776 1992. Unique Identifier : AIDSLINE ICDB/92684301
Adami C; Palleroni AV; Nalin C; Codner E; Hsu MC; Brunda MJ; Roche Res. Center, Hoffmann-La Roche Inc., Nutley, NJ 07110

Abstract: It has been previously shown that recombinant Tat protein (rTat), a HIV gene product that is necessary for viral replication in vitro, inhibits antigen- but not mitogen-induced lymphocyte proliferation. We have evaluated the immunosuppressive effects of rTat protein on macrophage (Mphi)-mediated tumor cell killing. Addition of rTat protein to the murine peritoneal Mphi cell line DJ2PM-PC results in a dose-dependent inhibition of tumoricidal activity induced by the combination of IFN-gamma and LPS. Furthermore, homotypic aggregation of the cells becomes evident after treatment of the Mphis with rTat protein and activators. Polyclonal antibody against rTat protein, but not a control serum, reversed both the inhibition of Mphi cytotoxicity and the cell aggregation, demonstrating that these phenomena are specifically due to the rTat protein. These novel properties of rTat protein may contribute to immunosuppression and pathogenicity in HIV infection.
Keywords: Animal Cell Aggregation/DRUG EFFECTS Cell Line Cytotoxicity, Immunologic/*DRUG EFFECTS Gene Products, tat/*PHARMACOLOGY *HIV Immune Tolerance Macrophages/*DRUG EFFECTS Mice Recombinant Proteins ABSTRACTKWDanimalcellaggregation/drugeffectscelllinecytotoxicity,immunologic/KWDdrugeffectsgeneproducts,tat/KWDpharmacologyKWDhivimmunetolerancemacrophages/KWDdrugeffectsmicerecombinantproteinsabstract
920730
M9271107

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .